AOCMF ARONJ Conference—Anti-osteoclastic drugs, impact on maxillofacial and bone
London, United Kingdom
12 Sep 2016
Download vCalendar file
Quick access
Description
It is our pleasure to announce and invite you to attend the AOCMF's first conference on ARONJ ('Anti-osteoclastic drugs and their impact on maxillofacial and orthopedic bone biology, surgery, disease, and treatment'. The conference brings together leading principal investigators of AOCMF ARONJ projects who will share their interim results and encourage debate and discussion on the topic. This conference is open to all those interested and involved in this research field.
Programs
Event program
Contributors
Risto Kontio  (Course Chair)
View all
Details
ID LONDONARONJ0916
Type AOCMF
Level Principles
Region Europe and Southern Africa
Language(s) English
Scope International
Academic status Non peer reviewed
Format Symposium
Content Debates, Lectures
Target audience Clinical investigations, CMF musculoskeletal oncology, ENT surgery, General surgery, Neurosurgery, Oral and maxillofacial surgery, Other, Plastic surgery, Research, Residency
Registration
Closing date12 Sep 2016
Statusclosed
Places66
Available places0
Cancellation policyNo refund for cancellations
Pricing
Swiss Francs 75.00 CHF
Available discounts Amount %
Residents discount -25.50 CHF 34%
Click here to become a member
Payment options and information
Payment is by credit card.

Conference fee is:
75 swiss francs
49.50 swiss francs for students (indicated as resident discount - with proof of identity)
Included services
Coffee breaks
Course materials
Complimentary hardcopy of the book "ARONJ Guide to Research"
Aperitif and Canapés

Background to AOCMF ARONJ Clinical Priority Program (CPP)
Bisphosphonates (Alendronate, Zolendronate, Pamidronate and others) and additional anti-osteoclastic drugs such as RANKL inhibitors (Denosumab) are among the most prescribed drugs in the world today. 26 million prescriptions for Alendronate in the US alone are used for treatment of postmenopausal osteoporosis and 250,000 patients with metastatic bone cancer are treated with high dose intravenous bisphosphonates. These drugs have been noted to have profound influences on oral and orthopedic health including exacerbation of dental diseases, osteonecrosis of the jaw requiring ablation, spiral fractures of the femur, bone pain, and spinal and other foramenal stenosis, are some of the areas of impact associated with anti-osteoclastic drugs. These medications have also been associated with a marked decrease in femoral neck fractures, compression fractures of the spine and other osteoporotic fractures such as wrist and humerus.

AOCMF launched a CPP program sponsoring research projects to investigate on the field of ARONJ and is now excited to share first interim results.

Contact(s)
Ms Mirjam Bucher (Project Coordinator, AOCMF R&D) ACVS Diplomate
Stettbachstr. 6
8600 Dübendorf
Switzerland
Phone+41442002470
Mobile+41794401339
Emailmirjam.bucher@aofoundation.org
Venue

Park Plaza County Hall Hotel London
1 Addington Street
London, SE1 7RY
United Kingdom

Park Plaza County Hall Hotel

 

Downloads and gallery
Final Program (3433kb)